地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18771997407
传真：18771997407
邮箱：sales@amyjet.com
艾美捷科技代理nanoComposix品牌纳米材料。
nanoComposix公司提供单分散和未集聚的金属和金属氧化物纳米材料。nanoComposix拥有数百种不同的材料、尺寸、形状和表面的纳米材料产品库存。
此外，nanoComposix公司已经定制生产了2000余种核心/外壳、生物功能化、荧光和磁性纳米复合材料，以满足客户需求。nanoComposix公司公司的产品包括：
（1）金纳米颗粒：金纳米颗粒结合了强大的等离子体光学特性和多功能的表面功能化能力；这些纳米颗粒可用于免疫诊断、生物传感器、传感、光学效应、纳米医学等广泛应用。
（2）银纳米颗粒：银纳米颗粒结合了强大的等离子体光学特性和抗菌能力；这些纳米颗粒可用于广泛的应用，包括导电复合材料、生物传感器、传感、光伏等。
（3）二氧化硅纳米颗粒：二氧化硅纳米颗粒结合了生物相容性、独特的光学特性和多功能的表面功能化能力；这些纳米颗粒可用于纳米医学、靶向药物递送、紫外线散射、催化、DNA/RNA
提取、粒径参考等广泛应用。
（4）磁性纳米颗粒：磁铁矿（氧化铁）纳米颗粒在环境温度下具有超顺磁性，具有高表面积与体积比；这些纳米颗粒可用于纳米医学、成像造影剂、药物递送、生物传感器等广泛应用。
（5）铂纳米颗粒：铂纳米颗粒结合了独特的等离子体光学特性和生物相容性；这些纳米颗粒可用于燃料电池技术、疗法、催化等广泛应用。
（6）铝纳米颗粒：铝（Al）纳米颗粒具有独特的光学、物理和化学特性，使其成为各种应用的候选者，从纳米光子学和催化到高能复合材料的制备。
（7）散装纳米颗粒制造：nanoComposix为全球研究人员和行业领导者提供超过20年的高质量金属和金属氧化物纳米材料制造经验。
（8）定制纳米颗粒和用于诊断的试剂。
< " data-original="http://antylia.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理nanoComposix品牌纳米材料"> 艾美捷科技代理nanoComposix品牌纳米材料
艾美捷科技代理Steraloids Inc. 全系列产品。
Steraloids致力于为研究者提供2700种不同的类固醇雄激素，雌激素，孕激素，cholestins、胆汁酸、激素和代谢产物。
Steroids for Research: 2700 different androgens, estrogens, cholestins, progestins, bile-acids, hormones, and metabolites. Synthetic of endogenous, synthesized to purified standards.
<<| 产品列表 | ||
| 产品名称 | 产品编号 | CAS# |
| 1,(5α)-ANDROSTEN-4-AZA-3-ONE-17β-(N-TERT-BUTYL-CARBOXAMIDE) | A4370-000 | CAS 98319-26-7 |
| 1, (5α)-ANDROSTEN-3, 17-DIONE | A4400-000 | CAS 571-40-4 |
| 1(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE | A4420-000 | CAS 153-00-4 |
| 1(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE ACETATE | A4421-000 | CAS No |
| 1,(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE ENANTHATE | A4444-000 | CAS 303-42-4 |
| 1,(5α)-ANDROSTEN-2- METHYL-17β- OL-3-ONE | A4448-200 | CAS 5197-58-0 |
| 2(5α)-ANDROSTEN-17α-METHYL, 17β-OL | A4900-000 | CAS 3275-64-7 |
| 2, (5α)-ANDROSTEN-17β-OL | A4960-000 | CAS 2639-53-4 |
| 2, (5α)-ANDROSTEN-17β-OL ACETATE | A4961-000 | CAS No |
| 4-ANDROSTEN-3α, 17α-DIOL | A5480-000 | CAS 15183-38-7 |
| 4-ANDROSTEN-3α, 17α-DIOL DIACETATE | A5490-000 | CAS No |
| 4-ANDROSTEN-3α, 17β-DIOL | A5500-000 | CAS 1852-61-5 |
| 4-ANDROSTEN-4-OL-3, 17-DIONE METHYL ETHER | A6507-000 | CAS No |
| 4-ANDROSTEN-6α-OL-3, 17-DIONE | A6520-000 | CAS 24704-84-5 |
| 5-ANDROSTEN-17β-ACETAMIDO-3β-OL ACETATE | A7320-000 | CAS No |
| 5-ANDROSTEN-17β-AMINO-3β-OL | A7400-000 | CAS 4350-66-7 |
| 5-ANDROSTEN-16α-BROMO-3β-OL-17-ONE | A7500-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE | A2080-000 | CAS 521-11-9 |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE ACETATE | A2081-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE 3-0-CARBOXYMETHYLOXIME | A2085-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE HEMISUCCINATE | A2090-000 | CAS No |
| 5β-ANDROSTAN-17β-OL-3-ONE | A3730-000 | CAS 571-22-2 |
| 5β-ANDROSTAN-17β-OL-3-ONE ACETATE | A3731-000 | CAS No |
| 5β-ANDROSTAN-17β-OL-3-ONE BENZOATE | A3733-000 | CAS No |
| A-NOR-5α-ANDROSTAN-2α, 17α-DIETHYNYL-2β, 17β-DIOL DIPROPIONATE | N0100-000 | CAS 56470-64-5 |
| 9(11), (5α)-ANDROSTEN-3, 17-DIONE | A8950-000 | CAS 15375-19-6 |
| 9(11), (5β)-ANDROSTEN-3α-OL-17-ONE | A9000-000 | CAS 571-49-3 |
| 9(11),(5β)-ANDROSTEN-3β,17α-DIOL | A8940-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CMO | A9258-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CARBOXYMETHYLOXIME : BSA | A9260-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CMO : HORSERADISHPEROXIDASE | A9264-000 | CAS No |
| 5, 15,-ANDROSTADIEN-3β-0L-17-ONE | A0602-000 | CAS 17921-64-1 |
| 1, 4-ANDROSTADIENE-3, 17-DIONE | A0100-000 | CAS 897-06-3 |
| 1, 4-ANDROSTADIEN-3, 17-DIONE 17-ETHYLENEKETAL | A0110-000 | CAS 2398-63-2 |
| 3, 5-ANDROSTADIEN-17β-OL | A0353-000 | CAS 2602-86-0 |
| 3, 5-ANDROSTADIEN-3-OL-17-ONE 3-ETHYL ETHER | A0380-000 | CAS 972-46-3 |
| 4, 6-ANDROSTADIEN-17α-METHYL-17β-OL-3-ONE | A0402-000 | CAS No |
| 5, 16-ANDROSTADIEN-17-CYANO-3β-OL | A0630-000 | CAS No |
| 1, 4-ANDROSTADIEN-17β-OL-3-ONE GLUCURONIDE | A0207-200 | CAS No |
| 1, 4-ANDROSTADIEN-17α-METHYL-17β-OL-3-ONE | A0130-040 | CAS 72-63-9 |
| 1, 4-ANDROSTADIEN-17α-METHYL-6β, 17β-DIOL-3-ONE-6-ACETATE | A0125-080 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID 3-ACETATE | A0681-000 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID ETHYL ESTER | A0685-000 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID METHYL ESTER | A0689-000 | CAS No |
| 5, 16-ANDROSTADIEN-3-ONE-17β-CARBOXYLIC ACID | A0695-000 | CAS No |
| 1, 4-ANDROSTADIEN-17α-OL-3-ONE | A0190-000 | CAS No |
| 1, 4-ANDROSTADIEN-6β,17β-DIOL-3-ONE | A0085-000 | CAS No |
| 4, 16-ANDROSTADIEN-3α-OL | A0555-000 | CAS 6306-63-0 |
| 1, 4-ANDROSTADIEN-17β-OL-3-ONE-2,4,6,6-d4 | A0200-040 | CAS 846-48-0 |
| 1, 4, 6-ANDROSTATRIEN-17β-OL-3-ONE ACETATE | A4201-000 | CAS No |
| 1, 4, 7-ANDROSTATRIEN-17β-OL-3-ONE | A4250-000 | CAS No |
| 4-CHOLESTEN-3β-OL ACETATE | C6101-000 | CAS No |
| 4-CHOLESTEN-3β-OL BENZOATE | C6103-000 | CAS No |
| 4-CHOLESTEN-2α-OL-3-ONE | C6180-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL 3-HEMISUCCINATE | C6520-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL 3-OLEATE | C6525-000 | CAS No |
| 5-CHOLESTEN-3, 25-DIOL, 25-SULPHATE, SODIUM SALT | C6538-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL-7-ONE | C6550-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL-7-ONE ACETATE | C6551-000 | CAS No |
| 5-, 25R-CHOLESTEN-3β, 26-DIOL | C6570-000 | CAS 20380-11-4 |
| 5-CHOLESTEN-24(S), 25-EPOXY-3β-OL | C6640-000 | CAS 77058-74-3 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~78% | C6680-000 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL -25,26,26,26,27,27,27 -D7 | C6680-015 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~54% | C6680-050 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~78% | C6680-080 | CAS 000083-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ACETATE | C6681-000 | CAS 000915-05-9 |
| 5-CHOLESTEN-24α-ETHYL-3β-OL CHLOROFORMATE | C6683-000 | CAS No |
| 5-CHOLESTEN-24-ETHYL-3-OL-7-ONE | C6684-000 | CAS 2034-74-4 |
| 5-CHOLESTEN-24(28)-ETHYLIDENE-3β-OL | C6685-000 | CAS 17605-67-3 |
| 5-CHOLESTEN-25-FLUORO-3βOL | C6688-000 | CAS No |
| 5-CHOLESTEN-24α-METHYL 3β-OL | C6700-000 | CAS 474-62-4 |
| 5-CHOLESTEN-24α-METHYL 3β-OL-30% 24β | C6700-010 | CAS 474-62-4 |
| 5-CHOLESTEN-24α-METHYL 3β-OL-BENZOATE | C6703-000 | CAS No |
| 5-CHOLESTEN-6-NITRO-3β-OL ACETATE | C6711-000 | CAS No |
| 5-CHOLESTEN-6-NITRO-3β-OL BENZOATE | C6713-000 | CAS No |
| 5-CHOLESTEN-3α-OL | C6730-000 | CAS No |
| 5-CHOLESTEN-3α-OL ACETATE | C6731-000 | CAS No |
| 5-CHOLESTEN-3β-OL | C6760-000 | CAS 57-88-5 |
| 5-CHOLESTEN-3β-OL-25,26,26,26,27,27,27-D7 | C6760-020 | CAS 57-88-5 |
| 5-CHOLESTEN-3β-OL ACETATE | C6761-000 | CAS 604-35-3 |
| 5-CHOLESTEN-3β-OL ACETOACETATE | C6762-000 | CAS No |
| 5-CHOLESTEN-3β-OL N-BUTYRATE | C6775-000 | CAS 521-13-1 |
| 5-CHOLESTEN-3β-OL BENZOATE | C6770-000 | CAS 604-32-0 |
| 5-CHOLESTEN-3-OL CAPROATE | C6780-000 | CAS No |
| 5-CHOLESTEN-3β-OL CAPRYLATE | C6785-000 | CAS No |
| 5-CHOLESTEN-3β-OL-(25R)CARBOXYLIC ACID | C6786-000 | CAS No |
| 5-CHOLESTEN-3β-OL-(25S)CARBOXYLIC ACID | C6787-000 | CAS No |
| 5-CHOLESTEN-3β-OL CHLOROACETATE | C6790-000 | CAS 3464-50-4 |
| 5-CHOLESTEN-3β-OL CHLOROFORMATE | C6795-000 | CAS 7144-08-3 |
| 5-CHOLESTEN-3β-OL CINNAMATE | C6800-000 | CAS 1990-11-0 |
| 5-CHOLESTEN-3β-OL N-DECYLATE | C6805-000 | CAS 1183-04-6 |
| 5-CHOLESTEN-3-OL DOCOSAHEXAENOATE(4,7,10,13,16,19) | C6807-000 | CAS No |
| 5-CHOLESTEN-3β-OL ETHYL ETHER | C6812-000 | CAS 98-61-96 |
| 5-CHOLESTEN-3β-OL FORMATE | C6815-000 | CAS 4351-55-7 |
| 5-CHOLESTEN-3β-OL GLUCOSIDURONATE, SODIUM SALT | C6821-000 | CAS No |
| 5-CHOLESTEN-3β-OL HEMISUCCINATE | C6823-000 | CAS 1510-21-0 |
| 5-CHOLESTEN-3β-OL N-HEPTYLATE | C6825-000 | CAS 1182-07-6 |
| 5-CHOLESTEN-3β-OL ISO-BUTYRATE | C6840-000 | CASNoCH Groups C31 H52 |
| 5-CHOLESTEN-3β-OL LAURATE | C6845-000 | CAS 190-8-11-8 |
| 5-CHOLESTEN-3β-OL METHYLCARBONATE | C6855-000 | CAS 15507-52-5 |
| 5-CHOLESTEN-3β-OL METHYL ETHER | C6860-000 | CAS 1174-92-1 |
| 5-CHOLESTEN-3β-OL MYRISTATE | C6865-000 | CAS 1989-52-2 |
| 5-CHOLESTEN-3β-OL OLEATE | C6870-000 | CAS 303-43-5 |
| 5-CHOLESTEN-3β-OL OLEYL ETHER | C6871-000 | CAS No |
| 5-CHOLESTEN-3β-OL PALMITATE | C6875-000 | CAS No |
| 5-CHOLESTEN-3β-OL PELARGONATE | C6880-000 | CAS 1182-66-7 |
| 5-CHOLESTEN-3-OL PHENYLPROPIONATE | C6890-000 | CAS 14914-99-9 |
| 5-CHOLESTEN-3β-OL PROPIONATE | C6895-000 | CAS 633-31-8 |
| 5-CHOLESTEN-3β-OL PYRIDINIUM SULPHATE | C6903-000 | CAS No |
| 5-CHOLESTEN-3β-OL STEARATE | C6904-000 | CAS 35602-69-8 |
| 5-CHOLESTEN-3β-OL SULPHATE, SODIUM SALT | C6905-000 | CAS 2864-50-8 |
| 5-CHOLESTEN-3β-OL P-TOLUENESULPHONATE | C6910-000 | CAS 1182-65-6 |
| 5-CHOLESTEN-3β-OL SULPHATE TRIETHYL AMMONIUM SALT | C6911-000 | CAS No |
| 5-CHOLESTEN-3β-OL N-VALERATE | C6915-000 | CAS 1182-07-6 |
| 5-CHOLESTEN-3β-OL-7-ONE | C6970-000 | CAS 566-28-9 |
| 5-CHOLESTEN-3β-OL-7-ONE ACETATE | C6971-000 | CAS No |
| 5-CHOLESTEN-3β-OL-7-ONE BENZOATE | C6973-000 | CAS No |
| 5-CHOLESTEN-3-OL-7-ONE-7-CARBOXYMETHYLOXIME | C6980-000 | CAS 566-28-9 |
| 5-CHOLESTEN-3-OL-22-ONE | C7020-000 | CAS 19243-30-2 |
| 5-CHOLESTEN-3-OL-22-ONE ACETATE | C7021-000 | CAS No |
| 5-CHOLESTEN-3β- OL-24-ONE | C7030-000 | CAS 17752-16-8 |
| 5-CHOLESTEN-3-ONE | C7050-000 | CAS 601-54-7 |
| 5-CHOLESTEN-7-ONE | C7060-000 | CAS No |
| 5-CHOLESTEN-3, 7α, 25-TRIOL | C7085-000 | CAS No |
| 5-CHOLESTEN-3β, 16β, 26(25R)-TRIOL | C7090-000 | CAS No |
| 5-CHOLESTEN-3, 17α, 20α-TRIOL | C7100-000 | CAS No |
| N-ACETYL-5-METHOXYTRYPTAMINE-α,α,β,β-D4 | Z0600-000 | CAS 73-31-4 |
| 5-CHOLESTEN-3β, 4α-DIOL | C6400-000 | CAS 34310-86-6 |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://antylia.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Steraloids"> Steraloids
艾美捷科技有限公司代理Mimotopes公司多肽及多肽合成相关产品。Mimotopes公司位于澳大利亚，可以提供2000余种多肽，100余种药物及化妆品肽，1000余种各类氨基酸及多肽合成用试剂。
Mimotopes公司的主要产品类别：
（1）多肽（Peptides）
库存普通多肽（Catalogue Peptides）
化妆品肽（Cosmetic Peptides）
药物肽（Pharmaceutical Peptides）
肽库（Off-the-Shelf Library）
（2）氨基酸（Amino Acids）
Z Amino Acids
Unusual Amino Acids
N methyl Amino Acids
Fmoc Amino Acids
Common Amino Acids
Boc amino acids
AA attached_to_2-Chlorotrityl_Resin
AA attached_to_Wang_Resin
（3）多肽合成试剂（Peptides Synthesis Reagents）
Coupling Reagents
Amino Alcohols
General Reagents
Linkers
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物。
笼型倍半硅氧烷，具有无机立方核和外部有机基团的有机-无机杂化化合物。倍半硅氧烷是一种有机硅化合物，其化学式为[RSiO3/2]n（R=H，烷基，芳基或烷氧基）。倍半硅氧烷是无色固体，采用笼状或聚合结构，具有Si-O-Si键和四面体Si顶点。倍半硅氧烷是多八面体倍半硅氧烷（POSS）的一种，作为陶瓷材料和纳米复合材料的前驱体引起了人们的关注。不同的取代基（R）可以连接到Si中心。这些分子是不寻常的，因为它们具有无机硅酸盐核和有机表面。硅芯具有刚性和热稳定性。
Hybrid Plastics致力于提供全球最高质量的POSS®材料。具有ISO 9001:2008的质量管理体系，艾美捷科技有限公司与Hybrid Plastics Inc.长期合作，致力于为中国用户提供：Acrylates-POSS、Alcohols-POSS、Amines-POSS、Carboxylic Acids-POSS、Epoxides-POSS、Fluoroalkyls-POSS、Halides-POSS、Methacrylates-POSS、Molecular Silicas-POSS、Norbornenyls-POSS、Olefins-POSS、PEGs-POSS、Silanes-POSS、Silanols-POSS、Thiols-POSS等化合物。
MA0736 Acryloxypropyl POSS Cage mixture 现货销售 
MA0735 Methacryloxypropyl POSS 现货销售
AM0270 AminopropylIsooctyl POSS 现货销售 
产品主要包括：
http://www.amyjet.com/Index/lists/catid/27/kid/28.html
<| 货号品名 | 规格 |
| AL0125 – Trans-cyclohexandiol Isobutyl POSS | 1kg |
| AL0130 – 1,2-Propanediolisobutyl POSS | 1kg |
| AM0265 – AminopropylIsobutyl POSS | 100g,500g,1kg |
| AM0270 – AminopropylIsooctyl POSS | 100g,500g,1kg |
| AM0281 (Neat) – N-Phenylaminopropyl POSS | 25g,50g,100g,500g,1kg |
| AM0281.01.30 – N-Phenylaminopropyl POSS | 50g,1kg |
| EP0408.01.30 – Epoxycyclohexyl ethyl POSS cage mixture 30% PGMEA | 100g,1kg |
| EP0409 – Glycidyl POSS cage mixture | 100g,1kg |
| EP0409.07.30 – Glycidyl POSS Nanosilica Dispersion | 1kg |
| EP3530 – POSS Bond EP3530 | 1 Quart, 1 Gallon |
| HC0304.11 Cyclohexylepoxy Glycidyl POSS | |
| HC0310.31 – Cyclohexylethylepoxy isoOctyl POSS | |
| HC0313.31 – Cyclohexylethylepoxy PEG POSS | |
| HC0407.11 – Glycidyl Methacryl POSS | |
| HC0407.13 – Glycidyl Methacryl POSS | |
| HC0407.31 – Glycidyl Methacryl POSS | |
| HC040713.332 Glycidyl Methacryl PEG POSS | |
| HC0413.53 – Glycidyl PEG POSS | |
| HC0507.53 – Trifluoropropyl Methacrylpropyl POSS | |
| HC0613.53 – Acrylic PEG | |
| HC07051013.2211 Methacrylpropyl Trifluoropropyl iso-Octyl PEG POSS | |
| HC0709.13 Methacrylpropyl iso-butyl POSS | |
| HC0710.13 – Methacryloxypropyl isoOctyl POSS | |
| HC0713.31 – Methacryloxypropyl PEG POSS | |
| HC1110.71 Vinyl iso-Octyl POSS | |
| MA0701 – Acryloxypropyl isobutyl POSS | 1kg |
| MA0702 – Methacrylpropyloisobutyl POSS | 1kg |
| MA0719 – Methacryloxypropyl isooctyl POSS | 1kg |
| MA0735 – Methacryloxypropyl POSS | |
| MA0736 – Acryloxypropyl POSS Cage mixture | 100g,1kg |
| MA0735.08.30 – Methacrylic POSS Nanosilica Dispersion | |
| MA0736.08.30 – Acrylic POSS Nanosilica Dispersion | |
| MA0737 – Alpha Methacryl POSS | |
| MS0802 – DodecaPhenyl POSS | 1kg |
| MS0805 – OctaIsooctyl POSS | 1kg |
| MS0825 – OctaIsobutyl POSS | 1kg |
| MS0860 – OctaTMA POSS | 1kg |
| PG1190 – MethoxyPEG POSS cage mixture | 100g,500g,1kg |
| PG1193 HC1013.31 – MethoxyPEGisoOctyl POSS | |
| PM1270 – Phenyl Silanol Resin | 100g |
| SH1310 – Octasilane POSS | 50g |
| SO1450 – Trisilanol isobutyl POSS | 100g,1kg |
| SO1455 – TriSilanollsooctyl POSS | 100g,1kg |
| SO1458 – Trisilanol phenyl POSS | 100g,1kg |
| TH1555 – Mercaptopropyl isooctyl POSS | 50g,100g |
" data-original="http://antylia.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物"> 艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物
艾美捷科技有限公司代理Lonza的生命科学相关产品，包括：
（1）Primary and Stem Cells - 原代及干细胞
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/48.html）
（2）Transfection - 转染系列产品
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/39.html）
（3）Endotoxin Detection - 内毒素检测相关产品
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/33.html）
（4）Electrophoresis - 电泳相关产品
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/25.html）
（5）Culture Medium and Reagents - 细胞培养基及相关试剂
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/5.html）
（6）Cell Analysis - 细胞分析相关产品
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/4.html）
（7）ADME and Toxicology - ADME及毒理学相关产品
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/2.html）
（8）3D Culture Products - 3D细胞培养相关产品
（http://www.amyjet.com/Index/lists/catid/27/kid/19/p/1.html）
LONZA(龙沙)：瑞士的制药化工巨头，龙沙集团是一家以生命科学为主导，在生物化学、精细化工、功能化学等行业均处于领先地位的全球性跨国公司，具有一百多年历史，总部位于瑞士巴塞尔，在欧洲、美洲、亚洲总共有35个研发和生产中心，其中LONZA的大部分生物技术产品在美国研发生产。LONZA(龙沙)主要生产生命科学产品以及多种类的精细和特殊化工产品，以高科技生物技术与优质产品闻名世界。
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://antylia.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
DiaMetra公司位于意大利Perugia，致力于为诊断行业提供高品质产品，包括标品和检测试剂盒，涉及的检测领域包括：唾液试剂盒、高血压及钙的代谢、自体免疫疾病、糖尿病指标检测、肿瘤标志物、固醇类激素、性激素、甲状腺激素检测等。
Diametra is dedicated to providing quality products and the highest level of service in its target diagnostics segments. Through innovation and total commitment we strive to create value for our people, our customers and for the shareholders.
As an organization we constantly strive for innovation, not simply in the products we bring to the market but also in the way we interact with our customers and with each other. This is grounded in our solution driven approach to partnership.
产品主要应用领域：
Saliva kits
Hypertension / Calcium Metabolism
Controls
Autoimmune Diseases
Diabetes Monitoring
Tumor Markers
Steroids Hormones
Fertility Proteic Hormones
Thyroid Monitoring
Circulating Immuno Complexes
Miscellaneous
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
ProImmune公司是免疫学功能检测多聚体产品和服务的提供者。产品包括重组的MHC Class I 五聚体和MHC Class II 六聚体，用于特异性的T 细胞免疫功能检测。广泛用于传染性疾病，自身免疫学疾病和移植等热门领域的基础，新药和临床研究。
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.
ProImmune公司产品：
Pro5®MHC Class I Pentamers
CD1d Tetramers
ProT2® MHC Class II Tetramers
ProM2® MHC Class II Monomers
thinkpeptides® Peptide Products
Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
艾美捷科技代理Diaclone品牌检测试剂。
Diaclone是一家集酶联免疫试剂盒、流式抗体为一体的公司，在炎症、肿瘤、免疫学领域深耕多年；ELISA 试剂盒可对细胞因子、趋化因子、 生长因子进行有效检测。Diaclone的产品线主要包括：细胞因子和细胞黏附分子的抗体：这些抗体被广泛应用于酶联免疫检测试剂盒中，用于检测和量化细胞因子和细胞黏附分子的表达水平。酶联免疫试剂盒（ELISA）：Diaclone提供多种规格和型号的ELISA试剂盒，用于检测各种生物样本中的特定抗原或抗体。这些试剂盒具有灵敏度高、特异性强、操作简便等特点。酶联免疫斑点检测试剂盒（ELISpot）：ELISpot技术是一种用于检测细胞分泌特定蛋白质（如细胞因子）的灵敏方法。Diaclone的ELISpot试剂盒可用于研究细胞免疫应答，如T细胞活性等。
" data-original="http://antylia.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Diaclone品牌检测试剂"> 艾美捷科技代理Diaclone品牌检测试剂
艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物。
笼型倍半硅氧烷，具有无机立方核和外部有机基团的有机-无机杂化化合物。倍半硅氧烷是一种有机硅化合物，其化学式为[RSiO3/2]n（R=H，烷基，芳基或烷氧基）。倍半硅氧烷是无色固体，采用笼状或聚合结构，具有Si-O-Si键和四面体Si顶点。倍半硅氧烷是多八面体倍半硅氧烷（POSS）的一种，作为陶瓷材料和纳米复合材料的前驱体引起了人们的关注。不同的取代基（R）可以连接到Si中心。这些分子是不寻常的，因为它们具有无机硅酸盐核和有机表面。硅芯具有刚性和热稳定性。
Hybrid Plastics致力于提供全球最高质量的POSS®材料。具有ISO 9001:2008的质量管理体系，艾美捷科技有限公司与Hybrid Plastics Inc.长期合作，致力于为中国用户提供：Acrylates-POSS、Alcohols-POSS、Amines-POSS、Carboxylic Acids-POSS、Epoxides-POSS、Fluoroalkyls-POSS、Halides-POSS、Methacrylates-POSS、Molecular Silicas-POSS、Norbornenyls-POSS、Olefins-POSS、PEGs-POSS、Silanes-POSS、Silanols-POSS、Thiols-POSS等化合物。
MA0736 Acryloxypropyl POSS Cage mixture 现货销售
MA0735 Methacryloxypropyl POSS 现货销售
AM0270 AminopropylIsooctyl POSS 现货销售
产品主要包括：
http://www.amyjet.com/Index/lists/catid/27/kid/28.html
<| 货号品名 | 规格 |
| AL0125 – Trans-cyclohexandiol Isobutyl POSS | 1kg |
| AL0130 – 1,2-Propanediolisobutyl POSS | 1kg |
| AM0265 – AminopropylIsobutyl POSS | 100g,500g,1kg |
| AM0270 – AminopropylIsooctyl POSS | 100g,500g,1kg |
| AM0281 (Neat) – N-Phenylaminopropyl POSS | 25g,50g,100g,500g,1kg |
| AM0281.01.30 – N-Phenylaminopropyl POSS | 50g,1kg |
| EP0408.01.30 – Epoxycyclohexyl ethyl POSS cage mixture 30% PGMEA | 100g,1kg |
| EP0409 – Glycidyl POSS cage mixture | 100g,1kg |
| EP0409.07.30 – Glycidyl POSS Nanosilica Dispersion | 1kg |
| EP3530 – POSS Bond EP3530 | 1 Quart, 1 Gallon |
| HC0304.11 Cyclohexylepoxy Glycidyl POSS | |
| HC0310.31 – Cyclohexylethylepoxy isoOctyl POSS | |
| HC0313.31 – Cyclohexylethylepoxy PEG POSS | |
| HC0407.11 – Glycidyl Methacryl POSS | |
| HC0407.13 – Glycidyl Methacryl POSS | |
| HC0407.31 – Glycidyl Methacryl POSS | |
| HC040713.332 Glycidyl Methacryl PEG POSS | |
| HC0413.53 – Glycidyl PEG POSS | |
| HC0507.53 – Trifluoropropyl Methacrylpropyl POSS | |
| HC0613.53 – Acrylic PEG | |
| HC07051013.2211 Methacrylpropyl Trifluoropropyl iso-Octyl PEG POSS | |
| HC0709.13 Methacrylpropyl iso-butyl POSS | |
| HC0710.13 – Methacryloxypropyl isoOctyl POSS | |
| HC0713.31 – Methacryloxypropyl PEG POSS | |
| HC1110.71 Vinyl iso-Octyl POSS | |
| MA0701 – Acryloxypropyl isobutyl POSS | 1kg |
| MA0702 – Methacrylpropyloisobutyl POSS | 1kg |
| MA0719 – Methacryloxypropyl isooctyl POSS | 1kg |
| MA0735 – Methacryloxypropyl POSS | |
| MA0736 – Acryloxypropyl POSS Cage mixture | 100g,1kg |
| MA0735.08.30 – Methacrylic POSS Nanosilica Dispersion | |
| MA0736.08.30 – Acrylic POSS Nanosilica Dispersion | |
| MA0737 – Alpha Methacryl POSS | |
| MS0802 – DodecaPhenyl POSS | 1kg |
| MS0805 – OctaIsooctyl POSS | 1kg |
| MS0825 – OctaIsobutyl POSS | 1kg |
| MS0860 – OctaTMA POSS | 1kg |
| PG1190 – MethoxyPEG POSS cage mixture | 100g,500g,1kg |
| PG1193 HC1013.31 – MethoxyPEGisoOctyl POSS | |
| PM1270 – Phenyl Silanol Resin | 100g |
| SH1310 – Octasilane POSS | 50g |
| SO1450 – Trisilanol isobutyl POSS | 100g,1kg |
| SO1455 – TriSilanollsooctyl POSS | 100g,1kg |
| SO1458 – Trisilanol phenyl POSS | 100g,1kg |
| TH1555 – Mercaptopropyl isooctyl POSS | 50g,100g |
" data-original="http://antylia.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物"> 艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：15172469628
传真：18327026838
邮箱：sales@amyjet.com
0.3772
